Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

As we approach 2025, the landscape of innovation continues to evolve at an unprecedented pace. Visionary leaders and pioneering brands are at the forefront, shaping industries, redefining consumer ...